ISMRM21 - Magnets & Microscopes: Can Novel MRI Techniques Replace Myocardial Biopsy?

Magnets & Microscopes: Can Novel MRI Techniques Replace Myocardial Biopsy?

Member-Initiated Symposium

Tuesday, 18 May 2021

Concurrent 2

18:00 - 20:00

Moderators: Michael Markl & David Sosnovik

Session Number: MIS-22

Parent Session: Magnets & Microscopes: Can Novel MRI Techniques Replace Myocardial Biopsy?

Session Number:MIS-22

Organizers
Rene Botnar, Michael Markl, David Sosnovik

Overview
This Symposium was proposed by the Cardiac MR study group. We talk in the cardiovascular MRI community all the time about tissue characterization, but most of our Ph.D. scientists have never heard a pathologist speak about how they approach the interpretation of myocardial biopsies. While biopsies remain the gold standard for tissue characterization of the heart, new "-omics" approaches (genomics, transcriptomics, proteomics…) are showing great promise. This area is also not one that most in our MRI community have had any access/exposure to. In this session, we will focus on the tissue characterization space with experts from three fields: Rick Mitchell, a pathologist and a world leader in cardiac pathology; Hannah Valantine, a cardiologist who has conducted pivotal studies into the use of blood based genomic biomarkers to detect transplant rejection and other myocardial pathologies; and three MRI physicists who are doing cutting-edge work in the development of new endogenous contrast techniques (DTI, CEST, T1rho) to detect and characterize pathological changes in the myocardium. These topics have been made all the more relevant over the last few months/years by the emergence of new entities including, but not limited to, immune checkpoint (chemotherapy) induced myocarditis, COVID myocarditis, the increase volume of cardiac transplants (increased/expanded donor pool) and the availability of new/initial therapies to treat cardiac amyloid.

Target Audience
Physicists, engineers, and physicians interested in cardiac MRI and in tissue characterization in general.

Educational Objectives
As a result of attending this course, participants should be able to:
Upon completion of this course, participants should be able to: - Explain the basic approach to interpreting myocardial biopsies and their strengths and limitation; - Explain how new "-omic" biomarkers might detect myocardial disease and their strengths and limitations; - Discuss the role of parametric T1/T2 mapping of the heart and how it compares to myocardial biopsy; and - Review the potential of investigative techniques (DTI, CEST, T1rho) to provide equivalent/better information than biopsy.

			What I Look for in a Myocardial Biopsy: A Pathologist's View Richard Mitchell Brigham & Women's Hospital, Harvard University
			What Can Diffusion Tensor MRI Detect? Elizabeth Tunnicliffe University of Oxford
			The Potential of CEST Moriel Vandsburger University of California, Berkeley
			MRI Relaxometry: Standard & Emerging Techniques Walter Witschey University of Pennsylvania
			All We Need Is Blood: The Case for Omics Hannah Valantine National Institutes of Health, Stanford University